ALP
AlphaTON Capital Corp.
NASDAQ · Healthcare · Biotechnology · VG
$3.38
−0.59%11
Insider buys (3m)
1
Insider sells (3m)
$304.7K
Net value (3m)
-69.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 13, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 5,150 | $3.80 |
| Oct 5, 2026 | Mitin Yury · officer: See Remarks | A-Award | 10,906 | $1.30 |
| Oct 5, 2026 | Mitin Yury · officer: See Remarks | Sale | 393 | $4.15 |
| Oct 5, 2026 | Mitin Yury · officer: See Remarks | A-Award | 4,944 | $0.00 |
| Oct 5, 2026 | Mitin Yury · officer: See Remarks | Purchase | 9,000 | $4.29 |
| Oct 5, 2026 | Mitin Yury · officer: See Remarks | Purchase | 3,657 | $3.52 |
| Sep 23, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 10,000 | $4.40 |
| Sep 17, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 10,382 | $4.07 |
| Sep 17, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 2,000 | $4.16 |
| Sep 17, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 4,265 | $4.05 |
| Sep 17, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 7,900 | $4.15 |
| Sep 14, 2026 | Villani Fiorenzo · director, officer: See Remarks | A-Award | 11,735 | $0.00 |
| Sep 14, 2026 | Kaiser Brittany · director, officer: Chief Executive Officer | A-Award | 10,906 | $1.30 |
| Sep 14, 2026 | Kaiser Brittany · director, officer: Chief Executive Officer | Purchase | 9,350 | $5.35 |
| Sep 14, 2026 | Kaiser Brittany · director, officer: Chief Executive Officer | A-Award | 7,416 | $0.00 |
| Sep 14, 2026 | Villani Fiorenzo · director, officer: See Remarks | A-Award | 10,906 | $1.30 |
| Sep 14, 2026 | Villani Fiorenzo · director, officer: See Remarks | Purchase | 7,000 | $5.07 |
| Sep 14, 2026 | Villani Fiorenzo · director, officer: See Remarks | A-Award | 12,359 | $0.00 |
| Sep 11, 2026 | Levitt Wesley Allen · officer: Chief Financial Officer | Purchase | 1,000 | $5.10 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 13, 2026